Payment overview · 2025
General Payments
$1,887.38
97 reported records · 18 companies
Healthcare provider profile · identity verified
Barry S Brown, DO
Allopathic & Osteopathic Physicians|Internal Medicine · LOW MOOR, VA · NPI 1184628737
Verified facts
What the public records show
CMS Open Payments records show Barry S Brown, DO received $1,887.38 in general payments during 2025 across 97 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $388.39 | 20.6% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $230.84 | 12.2% | 9 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $183.31 | 9.7% | 9 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $142.77 | 7.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $140.82 | 7.5% | 8 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.55 | 5.8% | 7 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $96.30 | 5.1% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $92.46 | 4.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $80.86 | 4.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.15 | 4.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $65.33 | 3.5% | 4 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $63.45 | 3.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $61.49 | 3.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $59.29 | 3.1% | 3 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.40 | 1.6% | 2 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.48 | 1.3% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.45 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.04 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,887.38 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $244.80 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $206.44 | 8 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $190.35 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $168.46 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $149.49 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $142.77 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $140.82 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.55 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.55 | 7 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $96.30 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.14 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $80.86 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $76.15 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.33 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $65.33 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $63.45 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.29 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.69 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $50.69 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $29.40 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.73 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $24.48 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.40 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $21.04 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 315 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 128 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 63 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
62 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1072 | 279 |
| Atorvastatin Calcium | Atorvastatin Calcium | 847 | 238 |
| Levothyroxine Sodium | Levothyroxine Sodium | 750 | 193 |
| Losartan Potassium | Losartan Potassium | 711 | 195 |
| Omeprazole | Omeprazole | 664 | 183 |
| Lisinopril | Lisinopril | 622 | 179 |
| Gabapentin | Gabapentin | 609 | 136 |
| Metformin Hcl | Metformin Hcl | 482 | 137 |
| Metoprolol Tartrate | Metoprolol Tartrate | 460 | 126 |
| Hydrochlorothiazide | Hydrochlorothiazide | 414 | 114 |
| Montelukast Sodium | Montelukast Sodium | 412 | 110 |
| Metoprolol Succinate | Metoprolol Succinate | 392 | 112 |
| Furosemide | Furosemide | 377 | 115 |
| Potassium Chloride | Potassium Chloride | 377 | 106 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 349 | 115 |
| Pantoprazole Sodium | Pantoprazole Sodium | 330 | 90 |
| Eliquis | Apixaban | 315 | 63 |
| Prednisone | Prednisone | 315 | 168 |
| Simvastatin | Simvastatin | 298 | 80 |
| Alprazolam | Alprazolam | 287 | 59 |
| Lovastatin | Lovastatin | 240 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 239 | 50 |
| Allopurinol | Allopurinol | 237 | 57 |
| Lorazepam | Lorazepam | 229 | 62 |
| Tramadol Hcl | Tramadol Hcl | 213 | 46 |
| Meloxicam | Meloxicam | 202 | 34 |
| Warfarin Sodium | Warfarin Sodium | 200 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 198 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 180 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 177 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 176 | 62 |
| Klor-Con M20 | Potassium Chloride | 176 | 63 |
| Ezetimibe | Ezetimibe | 170 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 41 |
| Clopidogrel | Clopidogrel Bisulfate | 161 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 153 | 31 |
| Sertraline Hcl | Sertraline Hcl | 150 | 32 |
| Bumetanide | Bumetanide | 147 | 39 |
| Clonazepam | Clonazepam | 146 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 41 |
| Spironolactone | Spironolactone | 143 | 38 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 140 | 38 |
| Carvedilol | Carvedilol | 131 | 36 |
| Ozempic | Semaglutide | 128 | 23 |
| Glipizide Er | Glipizide | 127 | 36 |
| Glipizide | Glipizide | 124 | 31 |
| Amoxicillin | Amoxicillin | 123 | 101 |
| Trazodone Hcl | Trazodone Hcl | 117 | 30 |
| Fenofibrate | Fenofibrate,micronized | 116 | 34 |
| Pregabalin | Pregabalin | 109 | 32 |
| Synthroid | Levothyroxine Sodium | 102 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 99 | 77 |
| Xarelto | Rivaroxaban | 99 | 17 |
| Metformin Hcl Er | Metformin Hcl | 98 | 28 |
| Nitroglycerin | Nitroglycerin | 98 | 79 |
| Januvia | Sitagliptin Phosphate | 89 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 85 | 21 |
| Atenolol | Atenolol | 83 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 80 | 20 |
| Fluconazole | Fluconazole | 79 | 40 |
| Temazepam | Temazepam | 79 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 75 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 47 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 74 | 43 |
| Donepezil Hcl | Donepezil Hcl | 73 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 21 |
| Famotidine | Famotidine | 72 | 25 |
| Cefdinir | Cefdinir | 68 | 53 |
| Clonidine Hcl | Clonidine Hcl | 68 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 62 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 62 | 11 |
| Bupropion Xl | Bupropion Hcl | 61 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 59 | 34 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 59 | 18 |
| Sucralfate | Sucralfate | 58 | 25 |
| Diazepam | Diazepam | 56 | 15 |
| Enalapril Maleate | Enalapril Maleate | 56 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 56 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 56 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 13 |
| Baclofen | Baclofen | 52 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 26 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Glimepiride | Glimepiride | 46 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 12 |
| Fenofibrate | Fenofibrate | 45 | 12 |
| Memantine Hcl | Memantine Hcl | 44 | suppressed |
| Trimethoprim | Trimethoprim | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 22 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 34 |
| Benazepril Hcl | Benazepril Hcl | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 26 |
| Cephalexin | Cephalexin | 33 | 28 |
| Digoxin | Digoxin | 33 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 32 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 12 |
| Ramipril | Ramipril | 31 | suppressed |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 30 | 30 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Klor-Con M10 | Potassium Chloride | 28 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 26 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Repatha Syringe | Evolocumab | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 18 |
| Jardiance | Empagliflozin | 20 | suppressed |
| Rybelsus | Semaglutide | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 19 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 19 | suppressed |
| Sotalol | Sotalol Hcl | 19 | suppressed |
| Verapamil Sr | Verapamil Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Rexulti | Brexpiprazole | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 15 |
| Fenofibric Acid | Fenofibric Acid (Choline) | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Clotrimazole | Clotrimazole | 13 | 11 |
| Colchicine | Colchicine | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,887.38 · 97 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CREON, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NEXLETOL, OTEZLA, Ohtuvayre, Ozempic, PURIFIED CORTROPHIN GEL, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error